FGF signaling in the osteoprogenitor lineage non-autonomously regulates postnatal chondrocyte proliferation and skeletal growth

Kannan Karuppaiah[1], Kai Yu[1,2], Joohyun Lim[3], Jianquan Chen[3, #], Craig Smith[1], Fanxin Long[3], and David M. Ornitz[1*]

Departments of [1]Developmental Biology, [3]Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110 USA. [2]Division of Craniofacial Medicine, Department of Pediatrics, University of Washington and Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101 USA.

[#]Current address: Orthopedic Institute, Soochow University, China

Key words: FGF Signaling; PTHLH; IHH; Skeletal Development; Endochondral bone formation; Osteoblast; Chondrocyte

*Corresponding author

David M. Ornitz
Washington University School of Medicine,
Department of Developmental Biology
Campus Box 8103,
660 S. Euclid Avenue,
Saint Louis, MO 63110 USA

Tel: 314-362-3908
Fax: 314-362-7058
Email: dornitz@wustl.edu

ABSTRACT

Fibroblast Growth Factor (FGF) signaling is important for skeletal development; however, cell-specific functions, redundancy, and feedback mechanisms regulating bone growth are poorly understood. FGF receptors 1 and 2 (*Fgfr1* and *Fgfr2*) are both expressed in the osteoprogenitor lineage. Double conditional knockout mice (DCKO) mice, in which both receptors were inactivated using an osteoprogenitor-specific Cre driver, appeared normal at birth; however, DCKO mice showed severe postnatal growth defects that include an ~50% reduction in body weight and bone mass, and impaired longitudinal bone growth. Histological analysis showed reduced cortical and trabecular bone in DCKO mice, suggesting cell autonomous functions of FGF signaling during postnatal bone formation. Surprisingly, DCKO mice also showed growth plate defects and an arrest in chondrocyte proliferation. We provide genetic evidence that revealed a non-cell autonomous feedback pathway regulating *Fgf9, Fgf18*, and *Pthlh* expression, which together led to increased expression and signaling of *Fgfr3* in growth plate chondrocytes and suppression of chondrocyte proliferation. These observations show that FGF signaling in the osteoprogenitor lineage is obligately coupled to chondrocyte proliferation and the regulation of longitudinal bone growth.

SUMMARY STATEMENT

Conditional ablation of *Fgfr1* and *Fgfr2* in the osteoblast lineage reveals a feed-forward loop controlling FGFR3 signaling and chondrocyte proliferation.

INTRODUCTION

Human genetic disease and conditional gene inactivation experiments in mice have demonstrated essential roles for FGFRs 1 and 2 in development of the appendicular and axial skeleton (Ornitz and Marie, 2002; Ornitz and Marie, 2015; Su et al., 2014). Although both of these receptors are expressed in the osteoprogenitor lineage, redundant functions of these FGFRs and mechanisms that couple FGFR signaling in the osteoprogenitor lineage to chondrogenesis and longitudinal bone growth are not known.

In mice, *Fgfr1* has been targeted with *T(brachyury)-Cre*, *Ap2-Cre, Prx1-Cre*, *Col2a1-Cre*, *Col1-Cre, OC(osteocalcin)-Cre,* and *Dmp1-Cre* (Jacob et al., 2006; Karolak et al., 2015; Li et al., 2005; Verheyden et al., 2005; Xiao et al., 2014; Yu and Ornitz, 2008; Zhang et al., 2014). With the exception of *Col1-Cre, OC-Cre,* and *Dmp1-Cre*, which target relatively late stages of development, inactivation of *Fgfr1* was in multiple cell lineages that include condensing mesenchyme, chondrocytes, and osteoprogenitors. Observed phenotypes for *Prx1-Cre* and *T-Cre* include impaired limb bud development, increased cell death, and reduced size of mesenchymal condensations (Li et al., 2005; Verheyden et al., 2005; Yu and Ornitz, 2008). *Col2a1-Cre* targets chondrocytes and osteoblasts, and inactivation of *Fgfr1* resulted in an expanded hypertrophic chondrocyte zone (Jacob et al., 2006; Karolak et al., 2015); however, whether this was a cell-autonomous function of FGFR1 in hypertrophic chondrocytes or a non-cell-autonomous effect of inactivation of *Fgfr1* in the osteoblast lineage could not be determined from these experiments. Use of *Col1-Cre* or *OC-Cre* to target *Fgfr1* in mature osteoblasts resulted in increased bone mass and osteoblast number and no reported effect on bone length (Jacob et al., 2006; Zhang et al., 2014). Use of *Dmp1-Cre* to target *Fgfr1* in osteocytes resulted in decreased osteocyte-specific gene expression but no overt skeletal phenotype (Xiao et al., 2014).

Mice in which the *Fgfr2c* splice variant has been inactivated (*Fgfr2c⁻/⁻*) were viable but showed reduced postnatal growth (Eswarakumar et al., 2002*). Fgfr2* has also been conditionally targeted with *Dermo1(Twist2)-Cre* or suppressed using RNA interference in limb bud mesenchyme. Inactivation of *Fgfr2* with *Dermo1-Cre*, which effectively targets the chondrocyte and osteoblast lineage, also showed that *Fgfr2* is necessary for postnatal bone growth (Yu et al., 2003). Suppression of *Fgfr2* expression in limb bud mesenchyme in the *Ap2-Cre* lineage showed that FGFR2 is important for digit and tarsal bone development and ossification (Coumoul et al., 2005). None of the *Fgfr2* gene inactivation studies provided a mechanism to explain decreased bone growth.

Fgfr1 and *Fgfr2* have considerable overlap in their expression patterns in developing limb bud and bone (Orr-Urtreger et al., 1991; Peters et al., 1992; Yu et al., 2003). Inactivation of *Fgfr1* and *Fgfr2* in limb mesenchyme with *Prx1-Cre* resulted in severe skeletal hypoplasia (Yu and Ornitz, 2008). Analysis of phenotypes in distal limb bud mesenchyme identified a role for FGFR signaling in regulating cell survival, but not proliferation (Yu and Ornitz, 2008). The severity of the phenotype in the limb bud precluded analysis of embryonic or postnatal skeletal development.

Fgfr3 is expressed in proliferating and prehypertrophic chondrocytes and functions to inhibit postnatal chondrogenesis (Chen et al., 2001; Havens et al., 2008; Naski et al., 1998; Ornitz and Marie, 2015; Su et al., 2014). Loss of function of FGFR3, either globally or specifically in chondrocytes leads to skeletal overgrowth in mice, sheep, and humans (Beever et al., 2006; Colvin et al., 1996; Deng et al., 1996; Makrythanasis et al., 2014; Ornitz and Marie, 2015; Toydemir et al., 2006; Zhou et al., 2015). The inhibitory activity of FGFR3 on growth plate chondrocytes explains the pathogenic consequences of gain of function mutations in

FGFR3 on suppressing pre-pubertal skeletal growth in Achondroplasia and related chondrodysplastic disorders (Laederich and Horton, 2012; Naski et al., 1998; Naski et al., 1996). The signaling mechanisms by which FGFR3 suppresses chondrogenesis involves activation of STAT1, ERK1/2, and p38, increased expression of *Snail1* (*Snai1*), decreased expression of AKT, and activation of protein phosphatase 2a (PP2a), which dephosphorylates (activates) the retinoblastoma family members, p107 and p130. Activation of p107 (and p130) and increased expression of the cell cycle inhibitor, p21$^{Waf1/Cip1}$ function to directly suppress chondrocyte proliferation (Aikawa et al., 2001; Cobrinik et al., 1996; Dailey et al., 2003; de Frutos et al., 2007; Kolupaeva et al., 2013; Kolupaeva et al., 2008; Kurimchak et al., 2013; Laplantine et al., 2002; Legeai-Mallet et al., 2004; Priore et al., 2006; Raucci et al., 2004; Su et al., 1997). Although much is known about signals downstream of FGFR3 in chondrocytes, the mechanisms that regulate FGFR3 expression and activation and coordinate osteogenesis and chondrogenesis are poorly understood.

Here we investigate cell-autonomous FGFR1 and FGFR2 signaling in the osteoprogenitor lineage. We show that inactivation of FGFR1 and FGFR2 with *Osx-Cre* (Rodda and McMahon, 2006) results in decreased bone mass. Unexpectedly, we found that loss of FGFR1/2 in the osteoprogenitor lineage has a profound effect on chondrogenesis and postnatal longitudinal bone growth. The mechanism by which osteoprogenitor FGFR1/2 signaling regulates chondrogenesis involves activation of FGFR3 expression and signaling in chondrocytes through reduction in the expression of parathyroid hormone related peptide (*Pthlh*) and increased expression of *Fgf9* and *Fgf18*, ligands that normally regulate postnatal endochondral bone growth.

RESULTS

Postnatal growth defects in mice lacking *Fgfr1* and *Fgfr2* in the osteoprogenitor lineage

Fgfr1 and *Fgfr2* are expressed in the perichondrium and periosteum during skeletal development (Yu et al., 2003). Both FGFR1 and FGFR2 have similar *in vitro* signaling potency and ligand response profiles to FGF9 and FGF18 (Zhang et al., 2006), ligands that have key roles in regulating skeletal development (Hung et al., 2016; Hung et al., 2007; Liu et al., 2007; Liu et al., 2002; Ohbayashi et al., 2002). In several tissues, including the limb bud, palate, lung, kidney, liver, cerebellum, epidermis, and inner ear, *Fgfr1* and *Fgfr2* show significant functional redundancy (Bohm et al., 2010; Huh et al., 2015; Meyer et al., 2012; Ornitz and Itoh, 2015; Poladia et al., 2006; Sims-Lucas et al., 2011; Smith et al., 2012; White et al., 2006; Yang et al., 2010; Yu et al., 2015; Yu and Ornitz, 2008). To study the roles of FGFR signaling in the osteoprogenitor-lineage the *Osx-GFP::Cre* (*Osx-Cre*) allele was crossed to floxed alleles of *Fgfr1* and *Fgfr2* (Rodda and McMahon, 2006; Trokovic et al., 2003; Yu et al., 2003). *Osx-Cre* efficiently targets the osteoprogenitor lineage (trabecular bone and cortical bone), bone marrow stroma, a small percentage of chondrocytes, and some other non-skeletal cell types (Chen et al., 2014a; Rodda and McMahon, 2006).

Osx-Cre;Fgfr1$^{f/f}$;Fgfr2$^{f/f}$ double conditional knockout (*Osx-Cre;DCKO*), *Fgfr1$^{f/f}$;Fgfr2$^{f/f}$* double floxed control (*DFF*), and *Osx-Cre* control mice appeared normal at birth. Body weight was not significantly different between *Osx-Cre;DCKO, DFF,* and *Osx-Cre* control mice before postnatal day 4 (P4) (Fig. 1A, supplementary material Fig. S1A). Inactivation of *Fgfr1* and *Fgfr2* in the *Osx-Cre* lineage was confirmed by quantitative PCR evaluation of mRNA isolated from cortical bone from P21 *DFF* and *Osx-Cre;DCKO* mice (supplementary material Fig. S2). Histological evaluation of embryonic day 18.5 (E18.5) *Osx-Cre;DCKO* proximal tibia showed an increased height of the hypertrophic chondrocyte zone and narrowing of the growth plate and

diaphysis, but no other changes in cortical, trabecular, or growth plate histology (Fig. 1B). Furthermore, bone architecture of *Osx-Cre;DCKO* mice, as determined by Alizarin-Red and Alcian Blue staining of P0 skeletons also showed slightly narrowed long bones, but normal mineralized regions and cartilaginous growth plates (Fig. 1C).

Osx-Cre;DCKO mice failed to gain normal body weight when compared to *DFF* or *Osx-Cre* control mice. This growth defect became statistically significant (p<0.05) after P4 (Fig. 1A). By three weeks of age, *DCKO* mice were approximately half normal size but otherwise healthy (Fig. 1A, D). Because *Osx-Cre* is active in some non-skeletal lineages, including stromal cells, adipocytes, perivascular cells in the bone marrow, olfactory glomerular cells, and a subset of gastric and intestinal epithelial cells (Chen et al., 2014a), we questioned whether inactivation of *Fgfr1* and *Fgfr2* with *Osx-Cre* could influence growth by affecting the nutritional or hormonal status of the mice. Analysis of bone density and total body fat content, using Dual Energy X-Ray Absorptiometry (DEXA), showed a 29±2% (n=4, p<0.01) decrease in bone mineral content in *Osx-Cre;DCKO* compared to *DFF* mice, but no significant change in body fat content (Fig. 1E). Additionally, litters were placed on a high fat, high calorie diet at birth until 5 weeks of age. On this diet, *Osx-Cre;DCKO* and *DFF* mice both showed an elevated (19±1%, n=4, p<0.05) body fat content but *Osx-Cre;DCKO* mice still showed a decrease in bone mineral content (30±1%, n=4, p<0.01). We conclude that the growth defect in *Osx-Cre;DCKO* mice is most likely a consequence of impaired FGF signaling in *Osx-Cre* targeted cell lineages within skeletal tissue and not a consequence of extrinsic hormonal or nutritional changes.

The *Osx-Cre* allele, by itself, has been reported to have variable effects on skeletal growth that could depend on genetic background (Huang and Olsen, 2015; Wang et al., 2015). To evaluate a potential contribution of the *Osx-Cre* allele in the mixed C57BL/6J; 129X1

background used in these studies, wild type hybrid mice were compared to littermate *Osx-Cre* mice by following growth and by endpoint skeletal micro CT and histological analysis. Growth curves for wild type and *Osx-Cre* mice revealed a slight delay in *Osx-Cre* mice at P30 that normalized after P36 (supplementary material Fig. S1A). Micro CT analysis of cortical and trabecular bone showed no significant difference in the bone volume to total volume (BV/TV) ratio or bone mineral density (BMD) between P21 wild type and *Osx-Cre* mice (supplementary material Fig. S1B, C). Growth plate histology and *Fgfr3* expression at P21 were also similar between wild type and *Osx-Cre* mice (supplementary material Fig. S1D,E). These studies show that the *Osx-Cre* allele has a minimal effect on bone growth on the genetic background used in these studies.

Decreased bone formation in *Osx-Cre;DCKO* mice

Radiographic analysis of intact skeletons of three-month-old mice revealed that *Osx-Cre;DCKO* mice had shorter bones and reduced bone density compared to control mice (Fig. 1F). The overall shape of the bones was normal. MicroCT analysis of intact long bones (femur, tibia) revealed that the *Osx-Cre;DCKO* mice had reduced trabecular and cortical bone (Fig. 1G). This was reflected in a significantly reduced trabecular and cortical BV/TV ratio and BMD (Fig. 1H). Consistent with the microCT analysis, von Kossa-stained histological sections of P21 tibia revealed a reduced area of mineralized cortical bone, trabecular bone (primary spongiosa), and secondary ossification centers in *Osx-Cre;DCKO* mice (Fig. 2A). Although *Osx-Cre;DCKO* mice clearly have less mineralized trabecular and cortical bone and thus decreased numbers of osteoblasts, histological analysis of the trabecular region revealed normal osteoblast density and similar intensity of type I collagen (*Col1*) expression in osteoblasts (Fig. 2B, C). Consistent with this, histomorphometric analysis revealed a normal number of osteoblasts (N.Ob) and osteoblast surface area (Ob.S), when normalized to bone surface area (Fig. 2D).

Decreased growth plate size in *Osx-Cre;DCKO* mice

Growth plate histology of P21 *Osx-Cre;DCKO* mice compared to *DFF* controls showed a significant decrease in the overall length of the growth plate (GP) and the length of the proliferating (columnar) chondrocyte zone (p) (24% and 36%, p< 0.02, respectively) (Fig. 3A,B). At this stage of postnatal development, the hypertrophic chondrocyte zone (h), which was expanded at E18.5, was not significantly different from controls. Normalization of the length of the hypertrophic zone could be due to compensatory changes in the number of available input cells (assessed by chondrocyte proliferation) and changes in distal loss of hypertrophic chondrocytes through apoptosis, degradation of the extracellular matrix, or differentiation into trabecular osteoblasts.

Chondrocyte proliferation in P21 mice was evaluated by BrdU labeling. *Osx-Cre;DCKO* mice showed a 58% reduction in chondrocyte proliferation (Fig. 3C,D). Cell death, evaluated by expression of activated caspase 3 immunostaining was decreased in distal hypertrophic chondrocytes in *Osx-Cre;DCKO* mice (supplementary material Fig. S3A,B), and matrix degradation potential, evaluated by measuring osteoclast number (N.Oc) and osteoclast surface (Oc.S) per bone surface area was not significantly different in *DFF* and *Osx-Cre;DCKO* mice (Fig. 3E, F). Collectively, these data suggest that normalization of the hypertrophic chondrocyte zone in P21 *Osx-Cre;DCKO* mice results from both decreased chondrocyte proliferation that is partially compensated for by decreased cell death in distal hypertrophic chondrocytes.

Decreased chondrocyte proliferation is due to effects of non cell-autonomous loss of *Fgfr1* and *Fgfr2*.

Given that *Osx-Cre* targets a small percentage of prehypertrophic and hypertrophic chondrocytes (Chen et al., 2014a) and *Fgfr1* is expressed in hypertrophic chondrocytes, it was necessary to determine if inactivation of *Fgfr1* (and *Fgfr2*) in growth plate chondrocytes could

contribute to the observed decrease in chondrocyte proliferation. The aggrecan enhancer-driven, tetracycline-inducible Cre (*ATC*) transgene allele, which efficiently targets proliferating and hypertrophic chondrocytes during embryonic development (Dy et al., 2012), was used to inactivate floxed alleles of *Fgfr1* and *Fgfr2*. Female mice carrying *ATC;Fgfr1^{f/f};Fgfr2^{f/f}* (*ATC;DCKO*) embryos were placed on doxycycline throughout gestation and pups were maintained on doxycycline until P21. In situ hybridization shows *Fgfr1* expression in hypertrophic chondrocytes in *DFF* control mice and decreased expression in *ATC;DCKO* mice (Fig. 3G). PCR analysis of isolated growth plates from P21 mice demonstrated inactivation of *Fgfr1* (Fig. 3H). However, at P21, *DFF* control mice and *ATC;DCKO* mice were of similar weight, and showed no difference in growth plate histology (Fig. 3I), or chondrocyte proliferation (Fig. 3J,K). We conclude from these data that FGFR1 (and FGFR2, which is not expressed in chondrocytes) does not have a major cell-autonomous impact on embryonic or postnatal chondrogenesis.

Increased expression of *Fgf9* and *Fgf18* in *Osx-Cre;DCKO* mice

We hypothesized that inactivation of *Fgfr1* and *Fgfr2* in the *Osx-Cre* lineage could lead to a compensatory upregulation of *Fgf9* or *Fgf18*, ligands that are each necessary for normal embryonic skeletal development (Hung et al., 2007; Liu et al., 2007; Liu et al., 2002; Ohbayashi et al., 2002) and together display marked redundancy in skeletal development (Hung et al., 2016). Because FGF9 and FGF18 are also thought to function as ligands that signal to FGFR3 during postnatal bone growth to negatively regulate chondrocyte proliferation, compensatory upregulation of *Fgf9* or *Fgf18* expression due to loss of FGFR1/2 signaling in the osteoprogenitor lineage could aberrantly activate FGFR3 in the growth plate and suppress chondrocyte proliferation. To test this hypothesis, we performed *in situ* hybridization analysis of paraffin fixed intact bone tissues and qRT-PCR on distal bone tissue from *DFF* and *Osx-*

Cre;DCKO mice. *In situ* analysis revealed that *Fgf9* expression was induced in perichondrial tissue, adjacent connective tissue, reserve, proliferating, and prehypertrophic chondrocytes of *Osx-Cre;DCKO* mice (Fig. 4A). Consistent with *in situ* expression, qRT-PCR analysis of distal bone tissue showed a ~3.5 fold increased *Fgf9* expression in tissue from *Osx-Cre;DCKO* compared to *DFF* mice (Fig. 4B). Analysis of the expression pattern of *Fgf18* by *in situ* hybridization showed increased expression in reserve, proliferating, and prehypertrophic chondrocytes in *Osx-Cre;DCKO* compared to *DFF* mice (Fig. 4C). Consistent with these data, qRT-PCR showed a ~1.5 fold increase in *Fgf18* expression in *Osx-Cre;DCKO* compared to *DFF* distal bone tissue (Fig. 4D).

Increased *Fgfr3* expression and signaling *Osx-Cre;DCKO* growth plate

Evaluation of *Fgfr3* expression by *in situ* hybridization revealed a striking increase in expression in *Osx-Cre;DCKO* compared to *DFF* mice in both proliferating and prehypertrophic chondrocytes (Fig. 5A). This increase was confirmed by qRT-PCR analysis of distal bone tissue from P21 distal femur and proximal tibia (Fig. 5B). The *Snail1* transcription factor is induced by FGFR3 and is required for the activation of both the STAT1 and MAPK branches of the FGFR3 signaling pathway (de Frutos et al., 2007). Consistent with increased FGFR3 expression and signaling, *Snail1* expression was highly increased in *Osx-Cre;DCKO* compared to *DFF* mice (Fig. 5C). Immunostaining for the chondrocyte-specific transcription factor, SOX9, showed mildly elevated levels of expression in *Osx-Cre;DCKO* compared to *DFF* mice (Fig. 5D).

Activation of FGF9 in the perichondrium suppresses chondrocyte proliferation.

The ability of FGF9 to signal from perichondrial tissue to growth plate chondrocytes has been inferred from phenotypes seen in *Fgf9[-/-]* embryos (Hung et al., 2007). Additionally, transgenic mice that overexpressed FGF9 in chondrocytes (*Col2a1-Fgf9*) showed short limbs and a smaller growth plate and died by 5 weeks of age (Garofalo et al., 1999). However, whether

FGF9 has the capacity to signal from periosteal and trabecular osteoblasts to growth plate chondrocytes during prepubertal growth was not known. To conditionally overexpress *Fgf9* in periosteal and trabecular osteoblasts, *Runx2-rtTA* (Chen et al., 2014b) and *TRE-Fgf9-ires-eGFP* (White et al., 2006) transgenic mice were mated to generate biallelic *Runx2-rtTA;TRE-Fgf9-ires-eGFP* (*RunxTFG*) mice. In the presence of doxycycline, GFP fluorescence was observed in the perichondrium, periosteum, and trabecular bone of *RunxTFG* mice, but not in proliferating or hypertrophic chondrocytes (Fig. 6A). Compared to control (single transgenic mouse), *RunxTFG* transgenic mice showed a significantly (p<0.01) reduced body weight at P21 (Fig. 6B). Growth plate histology revealed that compared to control, *RunxTFG* transgenic mice had significantly (p<0.01) smaller proliferating and hypertrophic chondrocyte zones compared to controls (Fig. 6C, D). The height of the trabecular zone in *RunxTFG* transgenic mice was reduced, but otherwise histologically normal, and osteoclast numbers and morphology appeared normal (Fig. 6C, E). Most notably, chondrocyte proliferation was significantly (p<0.001) reduced in *RunxTFG* transgenic mice compared to control mice (Fig. 6F, G). Finally, *in situ* hybridization revealed that activation of *Fgf9* in the perichondrium/periosteum and trabecular bone induced the expression of *Fgfr3* in proliferating chondrocytes (Fig. 6H).

PTHLH links _Osx-Cre_ lineage FGFR1/2 signaling to _Fgfr3_ expression and chondrocyte proliferation in the postnatal growth plate.

Indian hedgehog (IHH) and parathyroid hormone-related peptide (PTHLH) are critical regulators of endochondral bone growth (Kozhemyakina et al., 2015; Long and Ornitz, 2013). IHH stimulates chondrocyte proliferation and *Pthlh* expression, while PTHLH suppresses chondrocyte maturation and *Ihh* expression. Because we have observed apparent non-cell autonomous effects of loss of *Osx-Cre* lineage FGFR1 and FGFR2 on chondrocyte growth, it was important to examine the potential activity of other signaling pathways that regulate growth

plate function. Compared to controls, *Ihh* was decreased in the P21 growth plate of *Osx-Cre;DCKO* mice (Fig. 7A,B). Interestingly, we found that *Pthlh* expression was also reduced in reserve chondrocytes in *Osx-Cre;DCKO* mice (Fig. 7C). Quantitative RT-PCR analysis of distal bone tissue showed an overall reduction in *Pthlh* mRNA (Fig. 7D). Consistent with FGFR3 signaling suppressing *Ihh-Pthlh* expression (Chen et al., 2001; Li et al., 2010; Minina et al., 2002; Naski et al., 1998), in mice induced to overexpress *Fgf9*, expression of *Pthlh* was reduced in reserve zone chondrocytes (Fig. 7E).

Analysis of *Fgfr3* promoter function *in vitro* shows that *Fgfr3* expression could be directly regulated (suppressed) by PTHLH activation of Protein Kinase A (PKA) (McEwen et al., 1999). To test whether PTH signaling could suppress *Fgfr3* expression *in vivo* in *Osx-Cre;DCKO* mice that highly overexpress *Fgfr3*, *Osx-Cre;DCKO* mice were injected intermittently (daily) with PTH from P15 to P21, a treatment regimen known to stimulate the anabolic effects of PTH signaling on bone (Esen et al., 2015; Xie et al., 2012). Compared to control *Osx-Cre;DCKO* mice that were only injected with PBS, PTH injected *Osx-Cre;DCKO* mice showed an increase in the size of the growth plate, increased thickness of trabecular bone, decreased expression of *Fgfr3*, and increased chondrocyte proliferation (Fig. 7F-J).

DISCUSSION

The growth plate is a transient component of developing endochondral bone that mediates longitudinal bone growth from late stages of embryonic development through puberty (Hunziker and Schenk, 1989; Noonan et al., 1998). FGFR3 is a well-established negative regulator of postnatal bone growth, functioning in the growth plate in proliferating and prehypertrophic chondrocytes. Activating mutations in FGFR3 are responsible for Achondroplasia, the most common form of dwarfism in humans (Horton et al., 2007; Ornitz and Marie, 2015). As signaling pathways that function downstream of FGFR3 are well established,(Ornitz and Itoh, 2015) the identification of non-cell autonomous mechanisms that regulate FGFR3 expression and signaling and postnatal growth plate function are essential for further elucidating complex regulatory networks that control endochondral bone formation.

Inactivation of *Fgfr1* and *Fgfr2* in the *Osx-Cre* lineage disrupted a non cell-autonomous feedback loop resulting in activation of FGFR3 signaling in growth plate chondrocytes and suppression of chondrocyte proliferation and longitudinal bone growth (Fig. 8). The precise cell-type(s) that maintains this feedback loop is not known; however, it is likely to be an immature osteoprogenitor, as similar phenotypes are not observed when *Fgfr1* and *Fgfr2* are inactivated in mature osteoblasts with the *Osteocalcin-Cre* allele (unpublished data). A likely early event eliciting this phenotype is increased expression of *Fgf9* in osteoprogenitor cells in the perichondrium, resulting in increased signaling through FGFR3 in adjacent chondrocytes. Activation of FGFR3 inhibits *Ihh* expression and signaling in prehypertrophic chondrocytes (Naski et al., 1998), a factor that is required to maintain *Pthlh* expression in reserve and articular chondrocytes (Hilton et al., 2005; Koziel et al., 2005; St-Jacques et al., 1999; Vortkamp et al., 1996). Propagating events include increased *Fgfr3* expression and signaling in the growth plate, which may further suppress *Ihh* and *Pthlh* and increase *Fgf9* and *Fgf18* expression. Such non

cell-autonomous cellular signaling pathways thus coordinate osteoprogenitor development and longitudinal bone growth.

FGFR1/2 function in the osteoprogenitor lineage.

Although FGFR1 and FGFR2 signaling have robust functions in limb bud mesenchyme, their function in the osteoprogenitor lineage during embryonic development is surprisingly mild. *Osx-Cre;DCKO* mice were born alive and showed no patterning defects in the appendicular skeleton. However, *Osx-Cre;DCKO* mice exhibited a calvarial ossification defect at birth (data not shown) and a postnatal reduction in cortical bone growth that indicates that osteoprogenitor lineage FGFR signaling is required for osteoblast growth and maturation that is independent of chondrogenesis. The precise role of FGFR signaling in osteoblasts will require further investigation.

FGFR signaling in osteoprogenitor cells indirectly affects growth plate activity.

The most striking feature of *Osx-Cre;DCKO* mice was the profound reduction in chondrocyte proliferation and longitudinal bone growth. We posited that this phenotype resulted from non-cell autonomous changes in chondrocytes that are secondary to loss of FGFR1 and FGFR2 signaling in osteoprogenitor cells. Because *Osx-Cre* targets a small percentage of chondrocytes (Chen et al., 2014a), there remained a possibility that the observed phenotype could result from inactivation of *Fgfr1* and *Fgfr2* in chondrocytes. However, this is unlikely because *Fgfr1* expression is restricted to hypertrophic chondrocytes and *Fgfr2* is not expressed in proliferating or hypertrophic chondrocytes. Nevertheless, to rule out cell autonomous effects of FGFR1 and FGFR2 in chondrocytes, these genes were inactivated specifically in chondrocytes using the *ATC-Cre* allele. The normal development of *ATC-Cre;DCKO* mice demonstrated that inactivation of *Fgfr1* and *Fgfr2* in proliferating and hypertrophic chondrocytes does not significantly affect chondrogenesis or prepubertal longitudinal bone growth.

A second feature of the *Osx-Cre;DCKO* phenotype was the prominent increase in *Fgfr3* expression in proliferating and hypertrophic chondrocytes. *In vitro* analysis of the *Fgfr3* promoter identified a regulatory sequence that results in decreased promoter activity in response to cAMP (McEwen et al., 1999). This *in vitro* data suggested that the observed decrease in *Pthlh* expression could contribute to increased *Fgfr3* expression. In support of this model, intermittent injection of *Osx-Cre;DCKO* mice with PTH(1-34) peptide suppressed *Fgfr3* expression in chondrocytes and increased chondrocyte proliferation (Fig. 8).

A third feature of the *Osx-Cre;DCKO* phenotype was reduced bone volume and density. This could result from cell-autonomous effects of FGFR signaling in osteoblasts, or to the reduced levels of *Pthlh* expression. Haploinsufficiency of Pthlh results in osteopenia in mice (Miao et al., 2005), with similar morphologies to that observed in *Osx-Cre;DCKO* mice.

Regulation of embryonic vs. postnatal growth plate.

The experiments presented here focus on the postnatal growth plate of 21 day old *Osx-Cre;DCKO* mice. Although, the *Osx-Cre* allele used to target *Fgfr1* and *Fgfr2* is active as early as embryonic day 12.5 (Ono et al., 2014; Rodda and McMahon, 2006), the extent of the embryonic phenotype appears to be limited to expansion of the hypertrophic chondrocyte zone, similar to the phenotype observed when the *Col2-Cre* allele was used to inactivate *Fgfr1* (Jacob et al., 2006). Thus, FGFR1/2 signaling either does not have a major role in the osteoprogenitor lineage prior to establishment of a secondary ossification center and formation of a mature growth plate or the non cell-autonomous mechanism that we identified is not activated during embryonic development. Most studies investigating skeletal development focus on the embryonic growth plate. However, the postnatal growth plate is the developmental structure that accounts for the majority of organismal skeletal growth and, yet, gene expression patterns and

the molecular and cellular mechanisms that regulate the postnatal growth plate are poorly defined.

In the embryonic growth plate IHH is involved in a feedback loop that regulates *Pthlh* expression in the distal periarticular perichondrium (Kronenberg, 2003). However, in postnatal bone, there is a reorganization of the growth plate, and *Pthlh* expression shifts to reserve zone chondrocytes and IHH signaling (Gli1) and *Pth1r* expression remains prominent in reserve/proliferating and prehypertrophic chondrocytes, respectively (Chau et al., 2011; Chen et al., 2008; Koziel et al., 2004). Thus, in the postnatal growth plate, PTHLH and IHH responsive cells overlap with *Fgfr3* expression patterns.

Loss of FGFR1/2 signaling in perichondrial and osteoprogenitor cells may disrupt growth plate homeostasis by initially triggering increased expression of FGF9 and FGF18. We posit that these events lead to increased FGFR3 expression and signaling (modeled by forced expression of *Fgf9* in perichondrial cells and osteoblasts). Secondarily, increased FGFR3 signaling could suppress *Ihh* expression and signaling and lead to suppression of *Pthlh* in chondrocytes, leading to an aberrant feed forward signal that further increases the expression of *Fgfr3* (Fig. 8). The ability to block this feed forward loop by administration of PTH(1-34) supports a model in which PTHLH regulates communication between osteoprogenitors, chondroprogenitors, and growth plate chondrocytes in a mature postnatal growth plate.

Termination of skeletal growth.

Osx-Cre;DCKO mice show increased expression of *Fgf9* and *Fgf18* in reserve, proliferating, and prehypertrophic chondrocytes and in cells at the periphery of the growth plate that may include chondroprogenitors in the groove of Ranvier. This may represent an amplification of a normal feed forward induction of *Fgf9* and *Fgf18* that could function to

permanently suppress growth plate chondrocyte proliferation at puberty and suppress articular chondrocyte proliferation and differentiation in adults. This model is consistent with continued expression of endogenous *Fgf18* in the postnatal growth plate and perichondrium, and in adult articular chondrocytes (Ellsworth et al., 2002; Lazarus et al., 2007; Mori et al., 2014).

MATERIALS AND METHODS

Mice

Mice were housed in a pathogen-free facility and handled in accordance with standard use protocols, animal welfare regulations, and the *NIH Guide for the Care and Use of Laboratory Animals*. All protocols were approved by the Washington University Animal Studies Committee. *Osx-GFP::Cre (Osx-Cre)* (Rodda and McMahon, 2006)*, Fgfr1$^{f/f}$* (Trokovic et al., 2003)*, Fgfr2$^{f/f}$* (Yu et al., 2003)*,* aggrecan enhancer-driven, tetracycline-inducible Cre (*ATC*) (Dy et al., 2012), *Runx2-rtTA* (Chen et al., 2014b), *TRE-Fgf9-ires-eGFP* (White et al., 2006) have been previously described.

Homozygous floxed alleles of *Fgfr1* and *Fgfr2* are maintained as double flox mice (*DFF*) and are outbred to hybrid C57BL/6J;129X1 mice every second generation and then backcrossed to homozygosity. Double conditional knockout (*DCKO*) breeding males (*Osx-Cre;Fgfr1$^{f/f}$;Fgfr2$^{f/f}$*) were generated by crossing *Osx-Cre* mice with *DFF* mice, backcrossing to *DFF* and suppressing the Cre activity of *Osx-Cre* with doxycycline. To inactivate *Fgfr1/2* in the osteoprogenitor-lineage, *DFF* female mice were crossed with *Osx-Cre;DCKO* breeder male mice resulting in an 50% yield of *Osx-Cre;DCKO* mice and *DFF* controls. *Osx-Cre* control mice were generated by crossing *Osx-Cre;DCKO* mice or *Osx-Cre* mice to wild type hybrid mice. A similar breeding strategy was used to generate *ATC*;*DCKO* mice. To express *Fgf9* in the osteoblasts lineage, *Runx2-rtTA* mice (Chen et al., 2014b) were crossed to *TRE-Fgf9-ires-Gfp* (White et al., 2006) to generate *RunxTFG* double transgenic mice. Females were induced with doxycycline chow (Bio-Serv Inc. 200 mg/kg green pellets, S3888)) from E0 to P21. High fat high calorie diet included breeder chow (PicoLab® *Mouse. Diet* 20) supplemented with Nutri-Cal® (Patterson Veterinary Supply) from birth to 5 wk of age.

Body weights were measured on multiple litters two to three times per week until animals were sacrificed for analysis. Growth curves represent cumulative pooled data from multiple litters and overlapping time points covering the entire time course.

Histology, Immunohistochemistry, and Immunofluorescence

For histological analysis of long bones, intact femur-tibia were isolated, fixed in 4% PFA/PBS overnight at 4°C or fixed in 10% buffered formalin overnight at room temperature. Bones were rinsed in water several times and decalcified in 14% EDTA/PBS for two weeks. Paraffin embedded tissue section (5 μm) were stained with hematoxylin and eosin (H&E), tartrate resistant acid phosphatase (TRAP), VonKossa, or Alizarin-Red.

For immunohistochemistry, paraffin sections or cryo-sections were rehydrated and treated with 0.3% hydrogen peroxide in methanol for 15 min to suppress endogenous peroxidase activity. Antigen retrieval was achieved by microwaving the sections in 10 mM citrate buffer for 10 min followed by gradual cooling to room temperature. Sections were incubated overnight at 4°C with the following primary antibodies: SOX9 (Millipore, AB5535, rabbit polyclonal, 1:100), anti-active Caspase -3 (BD Pharmingen, #559565, 1:100). Fluorescently labeled Alexa Fluor 488 donkey anti-rabbit (Life Technologies, A-21206, 1:1000). Colorimetric detection used the ABC kit (Invitrogen #95-9943). Immunofluorescence imaging was performed on a Zeiss Apotome Fluorescence Microscope. Data is representative of at least three independent experiments.

For *in situ* hybridization analysis, tissues were fixed and decalcified at 4°C. For frozen sections, the tissues were fixed as described above and decalcified for 3 days, transferred to 30% sucrose (S0389, SIGMA) for 24 hr, embedded in OCT compound, sectioned at 5 μm, and stored at -20 until analysis. Non-radioactive *in situ* hybridization was performed as previously described (Naski et al., 1998). *In situ* probes: *Fgf9* (Colvin et al., 1999); *Fgf18* (Liu et al., 2002);

Fgfr3 (Peters et al., 1993); *Snail1* (Vega et al., 2004); *Pthlh* (Lee et al., 1996; Long et al., 2001); *Ihh* (Bitgood and McMahon, 1995); *Col1* (Rossert et al., 1995). Data is representative of at least three independent experiments.

Cell proliferation was determined by injecting U (5-Bromo-2' deoxyuridine, SIGMA, 9285) 0.1 mg/gram body weight 2 hr before tissues were harvested. Anti BrdU mouse monoclonal (BD Biosciences, #347580) was used at a 1:200 dilution. BrdU labeling was normalized to the total number of cells in the proliferating zone or to the area of the proliferating zone. Data were then normalized to that of *DFF* control mice. At least three mice and 2-3 sections per mouse were analyzed for each genotype.

Histomorphometry

H&E and TRAP stained sections were used for quantification of osteoblast and osteoclast number and surface, using BioQuant OSTEO 2010 software. Measurements of growth plate length in H&E stained sections were made using Canvas X software (ACD systems). All lengths were normalized to the total length of the *DFF* control growth plate. Statistical analysis (Student's t test) was based on measurements of tissue samples from at least three control and three experimental mice.

MicroCT and DEXA analysis

For microCT, intact long bones were isolated and fixed in 70% ethanol overnight at 4°C and then stored at -20°C until analysis. Bones were embedded in 1.5% agarose and scanned (μCT40, Scanco Medical). MicroCT analysis of trabecular and cortical bone was performed as follows: for trabecular bone, 100 to 150 sections were selected below the growth plate for reconstruction and quantification. For cortical bone quantification, 50 to 100 sections were selected from the mid diaphysis of the femur or tibia. Quantification was performed using

SCANCO Medical microCT systems software. Dual-Energy X-Ray Absorptiometry (DEXA, GE/Lunar PIXImus) was used for measurements of whole body bone density and body fat content. Data is representative of at least three mice per genotype.

Real time quantitative PCR

Distal bone, containing the growth plate, perichondrium, and trabecular bone was dissected. Immediately after isolation, the tissues were individually frozen in liquid nitrogen and stored at -80°C until analysis. Frozen tissues were pulverized in a dry ice cooled stainless steel flask with a ball bearing in a Micro Dismembrator (Sartorius) at 2000 RPM for 20 seconds. RNA was stabilized with Trisol (TRIsol Reagent, Ambion/RNA) and total RNA isolation was prepared according to the manufacturer's instructions. cDNA was synthesized using the iScript™Select cDNA synthesis Kit (#170-8841, BIO-RAD). mRNA expression was measured using TaqMan™ Fast Advanced Master Mix (#4444557, Life Technologies) and TaqMan™ assay probes for *Ihh*, *Pthlh*, *Fgf9*, *Fgf18*, and *Fgfr3*. *Hprt* was used a normalization control.

PTH treatment

For *in vivo* treatment of mice with PTH, 15 day-old *Osx-Cre;DCKO* mice were injected i.p. once per day (morning) with synthetic PTH-related peptide (I-34) (H-6630, Bachem) at a concentration of 80 μg/kg body weight or with PBS (control). Mice were injected for five days and then sacrificed at P21.

Statistics

The data are reported as the mean ± SD and changes with p values less than 0.05 were considered to be statistically significant. Data was analyzed using a two-tailed Student's *t*-test. Numbers of mice used per group per experiment are stated in the figure legends.

Acknowledgements

Author Contributions

Conceptualization and Methodology, K.K., K.Y., F.L., D.M.O.; Investigation, K.K., K.Y., J.L., J.C. C.S., D.M.O.; Writing–Original Draft, K.K., D.M.O.; Writing–Review & Editing, K.K., K.Y., F.L., D.M.O.; Funding Acquisition, Resources, and Supervision, F.L., D.M.O.

Development • Advance article

References

Aikawa, T., Segre, G. V. and Lee, K. (2001). Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. *J. Biol. Chem.* **276**, 29347-29352.

Beever, J. E., Smit, M. A., Meyers, S. N., Hadfield, T. S., Bottema, C., Albretsen, J. and Cockett, N. E. (2006). A single-base change in the tyrosine kinase II domain of ovine FGFR3 causes hereditary chondrodysplasia in sheep. *Anim. Genet.* **37**, 66-71.

Bitgood, M. J. and McMahon, A. P. (1995). Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. *Dev. Biol.* **172**, 126-138.

Bohm, F., Speicher, T., Hellerbrand, C., Dickson, C., Partanen, J., Ornitz, D. and Werner, S. (2010). FGF receptors 1 and 2 control chemically-induced injury and compound detoxification in regenerating livers of mice. *Gastroenterology*.

Chau, M., Forcinito, P., Andrade, A. C., Hegde, A., Ahn, S., Lui, J. C., Baron, J. and Nilsson, O. (2011). Organization of the Indian hedgehog--parathyroid hormone-related protein system in the postnatal growth plate. *J. Mol. Endocrinol.* **47**, 99-107.

Chen, J., Shi, Y., Regan, J., Karuppaiah, K., Ornitz, D. M. and Long, F. (2014a). Osx-Cre Targets Multiple Cell Types besides Osteoblast Lineage in Postnatal Mice. *PLoS One* **9**, e85161.

Chen, J., Tu, X., Esen, E., Joeng, K. S., Lin, C., Arbeit, J. M., Ruegg, M. A., Hall, M. N., Ma, L. and Long, F. (2014b). WNT7B promotes bone formation in part through mTORC1. *PLoS Genet* **10**, e1004145.

Chen, L., Li, C., Qiao, W., Xu, X. and Deng, C. (2001). A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. *Hum Mol Genet* **10**, 457-465.

Chen, X., Macica, C. M., Nasiri, A. and Broadus, A. E. (2008). Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormone-related protein in mice. *Arthritis Rheum.* **58**, 3788-3797.

Cobrinik, D., Lee, M. H., Hannon, G., Mulligan, G., Bronson, R. T., Dyson, N., Harlow, E., Beach, D., Weinberg, R. A. and Jacks, T. (1996). Shared role of the pRB-related p130 and p107 proteins in limb development. *Genes Dev.* **10**, 1633-1644.

Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G. and Ornitz, D. M. (1996). Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat. Genet.* **12**, 390-397.

Colvin, J. S., Feldman, B., Nadeau, J. H., Goldfarb, M. and Ornitz, D. M. (1999). Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene. *Dev. Dyn.* **216**, 72-88.

Coumoul, X., Shukla, V., Li, C., Wang, R. H. and Deng, C. X. (2005). Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. *Nucleic Acids Res* **33**, e102.

Dailey, L., Laplantine, E., Priore, R. and Basilico, C. (2003). A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. *J. Cell Biol.* **161**, 1053-1066.

de Frutos, C. A., Vega, S., Manzanares, M., Flores, J. M., Huertas, H., Martinez-Frias, M. L. and Nieto, M. A. (2007). Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. *Dev Cell* **13**, 872-883.

Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* **84**, 911-921.

Dy, P., Wang, W., Bhattaram, P., Wang, Q., Wang, L., Ballock, R. T. and Lefebvre, V. (2012). Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. *Dev Cell* **22**, 597-609.

Ellsworth, J. L., Berry, J., Bukowski, T., Claus, J., Feldhaus, A., Holderman, S., Holdren, M. S., Lum, K. D., Moore, E. E., Raymond, F., et al. (2002). Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. *Osteoarthritis Cartilage* **10**, 308-320.

Esen, E., Lee, S. Y., Wice, B. M. and Long, F. (2015). PTH Promotes Bone Anabolism by Stimulating Aerobic Glycolysis via IGF Signaling. *J. Bone Miner. Res.*

Eswarakumar, V. P., Monsonego-Ornan, E., Pines, M., Antonopoulou, I., Morriss-Kay, G. M. and Lonai, P. (2002). The IIIc alternative of Fgfr2 is a positive regulator of bone formation. *Development* **129**, 3783-3793.

Garofalo, S., Kliger-Spatz, M., Cooke, J. L., Wolstin, O., Lunstrum, G. P., Moshkovitz, S. M., Horton, W. A. and Yayon, A. (1999). Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. *J. Bone Miner. Res.* **14**, 1909-1915.

Havens, B. A., Velonis, D., Kronenberg, M. S., Lichtler, A. C., Oliver, B. and Mina, M. (2008). Roles of FGFR3 during morphogenesis of Meckel's cartilage and mandibular bones. *Dev Biol* **316**, 336-349.

Hilton, M. J., Tu, X., Cook, J., Hu, H. and Long, F. (2005). Ihh controls cartilage development by antagonizing Gli3, but requires additional effectors to regulate osteoblast and vascular development. *Development* **132**, 4339-4351.

Horton, W. A., Hall, J. G. and Hecht, J. T. (2007). Achondroplasia. *Lancet* **370**, 162-172.

Huang, W. and Olsen, B. R. (2015). Skeletal defects in Osterix-Cre transgenic mice. *Transgenic Res.* **24**, 167-172.

Huh, S. H., Warchol, M. E. and Ornitz, D. M. (2015). Cochlear progenitor number is controlled through mesenchymal FGF receptor signaling. *Elife* **4**.

Hung, I. H., Schoenwolf, G. C., Lewandoski, M. and Ornitz, D. M. (2016). A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development. *Dev Biol* **411**, 72-84.

Hung, I. H., Yu, K., Lavine, K. J. and Ornitz, D. M. (2007). FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. *Dev Biol* **307**, 300-313.

Hunziker, E. B. and Schenk, R. K. (1989). Physiological mechanisms adopted by chondrocytes in regulating longitudinal bone growth in rats. *J Physiol* **414**, 55-71.

Jacob, A. L., Smith, C., Partanen, J. and Ornitz, D. M. (2006). Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. *Dev Biol* **296**, 315-328.

Karolak, M. R., Yang, X. and Elefteriou, F. (2015). FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation. *Hum Mol Genet* **24**, 2552-2564.

Kolupaeva, V., Daempfling, L. and Basilico, C. (2013). The B55alpha regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes. *Mol Cell Biol* **33**, 2865-2878.

Kolupaeva, V., Laplantine, E. and Basilico, C. (2008). PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF. *PLoS One* **3**, e3447.

Kozhemyakina, E., Lassar, A. B. and Zelzer, E. (2015). A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation. *Development* **142**, 817-831.

Koziel, L., Kunath, M., Kelly, O. G. and Vortkamp, A. (2004). Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. *Dev Cell* **6**, 801-813.

Koziel, L., Wuelling, M., Schneider, S. and Vortkamp, A. (2005). Gli3 acts as a repressor downstream of Ihh in regulating two distinct steps of chondrocyte differentiation. *Development* **132**, 5249-5260.

Kronenberg, H. M. (2003). Developmental regulation of the growth plate. *Nature* **423**, 332-336.

Kurimchak, A., Haines, D. S., Garriga, J., Wu, S., De Luca, F., Sweredoski, M. J., Deshaies, R. J., Hess, S. and Grana, X. (2013). Activation of p107 by fibroblast growth factor, which is essential for chondrocyte cell cycle exit, is mediated by the protein phosphatase 2A/B55alpha holoenzyme. *Mol Cell Biol* **33**, 3330-3342.

Laederich, M. B. and Horton, W. A. (2012). FGFR3 targeting strategies for achondroplasia. *Expert reviews in molecular medicine* **14**, e11.

Laplantine, E., Rossi, F., Sahni, M., Basilico, C. and Cobrinik, D. (2002). FGF signaling targets the pRb-related p107 and p130 proteins to induce chondrocyte growth arrest. *J. Cell Biol.* **158**, 741-750.

Lazarus, J. E., Hegde, A., Andrade, A. C., Nilsson, O. and Baron, J. (2007). Fibroblast growth factor expression in the postnatal growth plate. *Bone* **40**, 577-586.

Lee, K., Lanske, B., Karaplis, A. C., Deeds, J. D., Kohno, H., Nissenson, R. A., Kronenberg, H. M. and Segre, G. V. (1996). Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. *Endocrinology* **137**, 5109-5118.

Legeai-Mallet, L., Benoist-Lasselin, C., Munnich, A. and Bonaventure, J. (2004). Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. *Bone* **34**, 26-36.

Li, C., Xu, X., Nelson, D. K., Williams, T., Kuehn, M. R. and Deng, C. X. (2005). FGFR1 function at the earliest stages of mouse limb development plays an indispensable role in subsequent autopod morphogenesis. *Development* **132**, 4755-4764.

Li, M., Seki, Y., Freitas, P. H., Nagata, M., Kojima, T., Sultana, S., Ubaidus, S., Maeda, T., Shimomura, J., Henderson, J. E., et al. (2010). FGFR3 down-regulates PTH/PTHrP receptor gene expression by mediating JAK/STAT signaling in chondrocytic cell line. *J. Electron Microsc. (Tokyo).* **59**, 227-236.

Liu, Z., Lavine, K. J., Hung, I. H. and Ornitz, D. M. (2007). FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. *Dev Biol* **302**, 80-91.

Liu, Z., Xu, J., Colvin, J. S. and Ornitz, D. M. (2002). Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. *Genes Dev.* **16**, 859-869.

Long, F. and Ornitz, D. M. (2013). Development of the endochondral skeleton. *Cold Spring Harb Perspect Biol* **5**, 1-20.

Long, F., Zhang, X. M., Karp, S., Yang, Y. and McMahon, A. P. (2001). Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. *Development* **128**, 5099-5108.

Makrythanasis, P., Temtamy, S., Aglan, M. S., Otaify, G. A., Hamamy, H. and Antonarakis, S. E. (2014). A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly. *Hum. Mutat.* **35**, 959-963.

McEwen, D. G., Green, R. P., Naski, M. C., Towler, D. A. and Ornitz, D. M. (1999). Fibroblast growth factor receptor 3 gene transcription is suppressed by cyclic adenosine 3 ',5 '-monophosphate - Identification of a chondrocytic regulatory element. *J. Biol. Chem.* **274**, 30934-30942.

Meyer, M., Muller, A. K., Yang, J., Moik, D., Ponzio, G., Ornitz, D. M., Grose, R. and Werner, S. (2012). FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin. *J. Cell Sci.* **125**, 5690-5701.

Miao, D., He, B., Jiang, Y., Kobayashi, T., Soroceanu, M. A., Zhao, J., Su, H., Tong, X., Amizuka, N., Gupta, A., et al. (2005). Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. *J Clin Invest* **115**, 2402-2411.

Minina, E., Kreschel, C., Naski, M. C., Ornitz, D. M. and Vortkamp, A. (2002). Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. *Dev Cell* **3**, 439-449.

Mori, Y., Saito, T., Chang, S. H., Kobayashi, H., Ladel, C. H., Guehring, H., Chung, U. I. and Kawaguchi, H. (2014). Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling. *J. Biol. Chem.* **289**, 10192-10200.

Naski, M. C., Colvin, J. S., Coffin, J. D. and Ornitz, D. M. (1998). Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. *Development* **125**, 4977-4988.

Naski, M. C., Wang, Q., Xu, J. and Ornitz, D. M. (1996). Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nat. Genet.* **13**, 233-237.

Noonan, K. J., Hunziker, E. B., Nessler, J. and Buckwalter, J. A. (1998). Changes in cell, matrix compartment, and fibrillar collagen volumes between growth-plate zones. *J. Orthop. Res.* **16**, 500-508.

Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N. and Takada, S. (2002). FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. *Genes Dev.* **16**, 870-879.

Ono, N., Ono, W., Nagasawa, T. and Kronenberg, H. M. (2014). A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. *Nat Cell Biol* **16**, 1157-1167.

Ornitz, D. M. and Itoh, N. (2015). The Fibroblast Growth Factor signaling pathway. *Wiley Interdiscip Rev Dev Biol* **4**, 215-266.

Ornitz, D. M. and Marie, P. J. (2002). FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. *Genes Dev.* **16**, 1446-1465.

---- (2015). Fibroblast growth factor signaling in skeletal development and disease. *Genes Dev.* **29**, 1463-1486.

Orr-Urtreger, A., Givol, D., Yayon, A., Yarden, Y. and Lonai, P. (1991). Developmental expression of two murine fibroblast growth factor receptors, flg and bek. *Development* **113**, 1419-1434.

Peters, K., Ornitz, D., Werner, S. and Williams, L. (1993). Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. *Dev Biol* **155**, 423-430.

Peters, K. G., Werner, S., Chen, G. and Williams, L. T. (1992). Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. *Development* **114**, 233-243.

Poladia, D. P., Kish, K., Kutay, B., Hains, D., Kegg, H., Zhao, H. and Bates, C. M. (2006). Role of fibroblast growth factor receptors 1 and 2 in the metanephric mesenchyme. *Dev Biol* **291**, 325-339.

Priore, R., Dailey, L. and Basilico, C. (2006). Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. *J Cell Physiol* **207**, 800-808.

Raucci, A., Laplantine, E., Mansukhani, A. and Basilico, C. (2004). Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. *J. Biol. Chem.* **279**, 1747-1756.

Rodda, S. J. and McMahon, A. P. (2006). Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. *Development* **133**, 3231-3244.

Rossert, J., Eberspaecher, H. and de Crombrugghe, B. (1995). Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. *J. Cell Biol.* **129**, 1421-1432.

Sims-Lucas, S., Cusack, B., Baust, J., Eswarakumar, V. P., Masatoshi, H., Takeuchi, A. and Bates, C. M. (2011). Fgfr1 and the IIIc isoform of Fgfr2 play critical roles in the metanephric mesenchyme mediating early inductive events in kidney development. *Dev Dyn* **240**, 240-249.

Smith, K. M., Williamson, T. L., Schwartz, M. L. and Vaccarino, F. M. (2012). Impaired motor coordination and disrupted cerebellar architecture in Fgfr1 and Fgfr2 double knockout mice. *Brain Res.* **1460**, 12-24.

St-Jacques, B., Hammerschmidt, M. and McMahon, A. P. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev.* **13**, 2072-2086.

Su, N., Jin, M. and Chen, L. (2014). Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. *Bone Research* **2**.

Su, W. C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W. A. and Fu, X. Y. (1997). Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. *Nature* **386**, 288-292.

Toydemir, R. M., Brassington, A. E., Bayrak-Toydemir, P., Krakowiak, P. A., Jorde, L. B., Whitby, F. G., Longo, N., Viskochil, D. H., Carey, J. C. and Bamshad, M. J. (2006). A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. *Am. J. Hum. Genet.* **79**, 935-941.

Trokovic, R., Trokovic, N., Hernesniemi, S., Pirvola, U., Vogt Weisenhorn, D. M., Rossant, J., McMahon, A. P., Wurst, W. and Partanen, J. (2003). FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. *Embo J* **22**, 1811-1823.

Vega, S., Morales, A. V., Ocana, O. H., Valdes, F., Fabregat, I. and Nieto, M. A. (2004). Snail blocks the cell cycle and confers resistance to cell death. *Genes Dev.* **18**, 1131-1143.

Verheyden, J. M., Lewandoski, M., Deng, C., Harfe, B. D. and Sun, X. (2005). Conditional inactivation of Fgfr1 in mouse defines its role in limb bud establishment, outgrowth and digit patterning. *Development* **132**, 4235-4245.

Vortkamp, A., Lee, K., Lanske, B., Segre, G. V., Kronenberg, H. M. and Tabin, C. J. (1996). Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* **273**, 613-622.

Wang, L., Mishina, Y. and Liu, F. (2015). Osterix-Cre transgene causes craniofacial bone development defect. *Calcif. Tissue Int.* **96**, 129-137.

White, A. C., Xu, J., Yin, Y., Smith, C., Schmid, G. and Ornitz, D. M. (2006). FGF9 and SHH signaling coordinate lung growth and development through regulation of distinct mesenchymal domains. *Development* **133**, 1507-1517.

Xiao, Z., Huang, J., Cao, L., Liang, Y., Han, X. and Quarles, L. D. (2014). Osteocyte-specific deletion of Fgfr1 suppresses FGF23. *PLoS One* **9**, e104154.

Xie, Y., Su, N., Jin, M., Qi, H., Yang, J., Li, C., Du, X., Luo, F., Chen, B., Shen, Y., et al. (2012). Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. *Hum Mol Genet*.

Yang, J., Meyer, M., Muller, A. K., Bohm, F., Grose, R., Dauwalder, T., Verrey, F., Kopf, M., Partanen, J., Bloch, W., et al. (2010). Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. *J. Cell Biol.* **188**, 935-952.

Yu, K., Karuppaiah, K. and Ornitz, D. M. (2015). Mesenchymal fibroblast growth factor receptor signaling regulates palatal shelf elevation during secondary palate formation. *Dev Dyn* **244**, 1427-1438.

Yu, K. and Ornitz, D. M. (2008). FGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axis. *Development* **135**, 483-491.

Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E. N., Towler, D. A. and Ornitz, D. M. (2003). Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. *Development* **130**, 3063-3074.

Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M. and Ornitz, D. M. (2006). Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J. Biol. Chem.* **281**, 15694-15700.

Zhang, Y., Su, N., Luo, F., Wen, X., Tang, Y., Yang, J., Chen, S., Jiang, W., Du, X. and Chen, L. (2014). Deletion of Fgfr1 in Osteoblasts Enhances Mobilization of EPCs into Peripheral Blood in a Mouse Endotoxemia Model. *Int J Biol Sci* **10**, 1064-1071.

Zhou, S., Xie, Y., Tang, J., Huang, J., Huang, Q., Xu, W., Wang, Z., Luo, F., Wang, Q., Chen, H., et al. (2015). FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling. *PLoS Genet* **11**, e1005214.

Figures

Figure 1. Postnatal growth defects in mice lacking Fgfr1 and Fgfr2 in the osteoprogenitor lineage.

A. Growth curve of control (*DFF*) and *Osx-Cre;DCKO* (*DCKO*) mice showing reduced growth of *DCKO* mice after P4 (data is pooled from 35 *DFF* mice and 26 *DCKO* mice). Not all mice were weighed at every time point. B. Proximal tibia histology (H&E) of *DFF* and *DCKO* mice at E18.5 showing a normal proliferating chondrocyte zone (p) and an expanded hypertrophic chondrocyte zone (h). C. Alizarin-Red and Alcian Blue staining of whole skeleton at P0 showing similar skeletal architecture of control and *DCKO* mice. D. *DFF* and *DCKO* mice at P21 showing smaller size of *DCKO* compared to control. E. Whole body DEXA analysis of *DFF* and *DCKO* mice (age 24-26 days, n=4) showing normal body fat content. F. Radiographic images of hindlimb (left) and forelimb (right) of three month-old *DFF* and *DCKO* mice showing reduced bone density of *DCKO* compared to control. G. Micro CT analysis of *DFF* and *DCKO* mice at P21 showing reduced trabecular and cortical bone in *DCKO* mice. H. Quantification of micro CT showing reduced cortical and trabecular bone volume to total volume ratio (BV/TV) and bone mineral density (BMD) in *DCKO* mice (n=3); Error bars, SD; *$P<0.05$; **$P<0.01$.

Figure 2. Decreased cortical and trabecular bone formation in *Osx-Cre;DCKO* mice

A. Histology of *DFF* and *DCKO* proximal tibia of P21 mice, showing reduced mineralized bone (von Kossa stain) in *DCKO* mice. B: Histology of *DFF* and *DCKO* mice (H&E stain) showing normal osteoblast morphology in the trabecular region adjacent to the chondro-osseous junction (asterisk). C. Type I collagen (*Col1*) expression detected by *in situ* hybridization in *DFF* and *DCKO* mice. D: Histomorphometry of *DFF* and *DCKO* mice (n=3) showing normal osteoblast number per bone surface area and normal osteoblast surface per bone surface. Arrows in B and C indicate osteoblasts. Scale bars: A, 500 μm; B, C, 50 μm. ns, non significant.

Figure 3. Decreased growth plate size and Decreased chondrocyte proliferation in *Osx-Cre; DCKO* mice

A. Histology (H&E) of the distal femur showing smaller growth plate and trabecular bone thickness in P21 *Osx-Cre;DCKO* compared to *DFF* mice. inset, 2X magnification. B. Growth plate measurements showing reduced total growth plate and proliferative zone length, and normal hypertrophic zone length in P21 *Osx-Cre;DCKO* mice compared to *DFF* mice. Data is normalized to the total growth plate height of *DFF* mice (n=3). C. BrdU immunohistochemistry showing reduced chondrocyte proliferation in *Osx-Cre;DCKO* compared to DFF mice. D. Quantification of BrdU labeled cells in the proliferating chondrocyte zone of DFF and *Osx-Cre;DCKO* growth plates (n=6, expressed as percent of control). E. TRAP staining (red) of DFF and *Osx-Cre;DCKO* proximal tibia. F. Histomorphometric analysis showing no difference in osteoclast number per bone surface, and normal osteoclast surface per bone surface of *DFF* and *Osx-Cre;DCKO* mice. G. Expression of *Fgfr1* (*in situ* hybridization) in the proximal tibia showing reduced expression in hypertrophic chondrocytes in *ATC;DCKO* compared to *DFF* mice. inset, 2X magnification. H. Confirmation of deletion of *Fgfr1* in the growth plate of *ATC;DCKO* mice: flox, unrecombined *Fgfr1* flox allele; del, *Fgfr1* deleted allele; Cre, *Cre* recombinase allele; M, markers (nt). I. Histology (H&E) of distal femur showing similar growth plate size in *DFF* and *ATC;DCKO* mice. J. BrdU immunohistochemistry showing no difference in chondrocyte proliferation in *DFF* and *ATC;DCKO* growth plate. K. Quantification of BrdU labeled cells in the proliferating chondrocyte zone on *DFF* and *ATC;DCKO* growth plates (n=3, expressed as percent of control). p, proliferating chondrocytes; h, hypertrophic chondrocytes; tb, trabecular bone. Scale bars: A, C, I, 200 μm; E, G, J, 100 μm; Error bars, SD; *P<0.02; **P<0.001; ns, not significant.

Figure 4. Increased expression of *Fgf9* and *Fgf18* in *Osx-Cre;DCKO* mice

A. Expression of *Fgf9* (*in situ* hybridization) in *DFF* and *Osx-Cre;DCKO* proximal tibia of P21 mice showing increased expression in the perichondrium, reserve, proliferating, and prehypertrophic chondrocytes of *Osx-Cre;DCKO* mice. B. qRT-PCR analysis of *Fgf9* expression in *DFF* and *Osx-Cre;DCKO* proximal tibia metaphysis (n=3). C. Expression of *Fgf18* (*in situ* hybridization) in P21 DFF and *Osx-Cre;DCKO* proximal tibia showing increased expression in articular cartilage, proliferating, and prehypertrophic chondrocytes in the growth plate and in trabecular bone of *Osx-Cre;DCKO* mice. D. qRT-PCR analysis of *Fgf18* expression in *DFF* and *Osx-Cre;DCKO* proximal tibia metaphysis (n=3). rc, reserve chondrocytes; p, proliferating chondrocytes; h, hypertrophic chondrocytes; ac, articular chondrocytes; tb, trabecular bone; pc, perichondrium. Scale bars: A, D, 100 μm; Error bars, SD; *$P<0.05$; **$P<0.002$.

Figure 5. Increased *Fgfr3* expression and signaling in *Osx-Cre;DCKO* mice

A,C. Expression (*in situ* hybridization) of *Fgfr3* (A) and *Snail1* (C) in *DFF* and *Osx-Cre;DCKO* distal femur. B. qRT-PCR analysis of *Fgfr3* expression in *DFF* and *Osx-Cre;DCKO* proximal tibia and distal femur metaphysis (n=3). D. Immunohistochemistry of *DFF* and *Osx-Cre;DCKO* proximal tibia showing mildly increased SOX9 in *Osx-Cre;DCKO* compared to *DFF* mice. p, proliferating chondrocytes; h, hypertrophic chondrocytes; tb, trabecular bone. Scale bars: A, C, D, 100 μm; Error bars, SD; *$P<0.05$.

Figure 6. Activation of *Fgf9* in the perichondrium suppresses chondrocyte proliferation.

A. Fluorescence imaging of induced GFP expression in trabecular bone (tb), cortical bone (e, endosteum; po, periosteum) and perichondrium (pc) of *RunxTFG* mice. GFP was not observed in hypertrophic chondrocytes (h). B. Decreased body weight of P21 *RunxTFG* mice (n=3) compared to *Runx2-rtTA* single transgenic control (n=4). C. Histology (H&E) of the proximal tibia showing a smaller growth plate in P21 *RunxTFG* compared to *Runx2-rtTA* single transgenic control. D. Growth plate measurements showing reduced total growth plate, proliferative zone, and hypertrophic zone size in P21 *RunxTFG* mice. E. TRAP staining of P21 control and *RunxTFG* mice showing normal osteoclast number. F: BrdU immunohistochemistry showing reduced chondrocyte proliferation in *RunxTFG* compared to control P21 mice. G. Quantification of BrdU labeled cells in the proliferating chondrocyte zone of P21 control and *RunxTFG* growth plates (n=3). H. Expression of *Fgfr3* (*in situ* hybridization) in P21 control and *RunxTFG* distal femur. rc, reserve chondrocytes; p, proliferating chondrocytes; h, hypertrophic chondrocytes; tb, trabecular bone. Scale bars: A1,A3,C-H 100 µm; A2, 20 µm; Error bars, SD; *P<0.01; **P<0.001.

Figure 7. Rescue of the *Osx-Cre;DCKO* growth plate phenotype by administration of PTH(1-34).

A. Expression of *Ihh* (*in situ* hybridization) in P21 *DFF* and *Osx-Cre;DCKO* distal femur showing decreased expression in the growth plate of *Osx-Cre;DCKO* mice. B. qRT-PCR analysis of *Ihh* expression in DFF and *Osx-Cre;DCKO* proximal tibia metaphysis (n=3). C. Expression of *Pthlh* (*in situ* hybridization) in P21 *DFF* and *Osx-Cre;DCKO* distal femur showing decreased expression in the peripheral growth plate in *Osx-Cre;DCKO* mice (inset: 2X magnification). D. qRT-PCR analysis of *Pthlh* expression in *DFF* and *Osx-Cre;DCKO* proximal tibia metaphysis (n=3). E. Expression of *Pthlh* in P21 control and *RunxTFG* proximal tibia. F. Histology (H&E) of the proximal tibia showing a larger growth plate and increased trabecular bone in P21 PTH treated compared to PBS (control) treated *Osx-Cre;DCKO* mice. G. Growth plate measurements showing increased total growth plate, proliferative, and hypertrophic zone size in PTH treated (n=3) compared to PBS treated (n=4) mice. H. Expression of *Fgfr3* (*in situ* hybridization) in the distal femur of P21 PTH treated compared to PBS (control) treated *Osx-Cre;DCKO* mice. I. BrdU immunohistochemistry showing increased chondrocyte proliferation in P21 PTH treated compared to PBS (control) treated *Osx-Cre;DCKO* mice. J. Quantification of BrdU labeled cells in the proliferating chondrocyte zone of PTH treated compared to PBS (control) treated *Osx-Cre;DCKO* mice (n=3). rc, reserve chondrocytes; p, proliferating chondrocytes; ph, prehypertrophic chondrocytes; h, hypertrophic chondrocytes; tb, trabecular bone. Scale bars: A, C, 50µm; E, F, H, I, 100 µm; Error bars, SD; *$P<0.05$; **$P<0.005$; ***$P<0.001$.

Figure 8. Model of FGF regulated interactions between osteoprogenitor lineages and growth plate chondrocytes in postnatal endochondral bone growth.

(A) FGFR1 and FGFR2 in the osteoprogenitor lineage are regulated by FGF9 expressed in osteoprogenitors and adjacent connective tissue and periosteum. Inactivation of FGFR1 and FGFR2 results in compensatory increased expression of *Fgf9*, which (B) aberrantly activates FGFR3 and downstream Snail1 to suppress chondrocyte proliferation and hypertrophy. Increased FGFR3 signaling also promotes *Fgf9* and *Fgf18* expression in chondrocytes and suppresses expression of *Ihh* and *Pthlh*. PTHLH functions to suppress *Fgfr3* expression and reduced *Pthlh* contributes to increased *Fgfr3* expression. The aberrant activation of FGFR3 (expression and signaling in chondrocytes) may initiate a feed-forward signaling loop in chondrocytes that functions to terminate chondrogenesis. HS, heparan sulfate.